🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to join Twitter by sharing our latest paper on human B cell development in collaboration with Mats Bemark School of Immunology & Microbial Sciences Guy's and St Thomas' Research biorxiv.org/content/10.110…

Reda from our lab presenting the results of out profile of immune and cancer cells in response to immunotherapy The Francis Crick Institute School of Cancer & Pharmaceutical Sciences ITN CONTRA Cancer Research UK #CrickCancerConf

In patients with microsatellite-unstable colorectal tumors, pembrolizumab led to longer progression-free survival and was less toxic than standard care.

Check out our deep characterisation of immune checkpoint blockade response among CRC patients! Beyond TMB, we show many other potential molecular and cellular players in response determination, incl. clonality, immune-related deregulation, WNT, and macrophage infiltration #ICB

Struggling with multiplexed imaging data from IMC, CODEX, MIBI, cycIF? So were we… until Michele, Reda, Damjan, Amelia Acha Sagredo and Lucia in the lab developed a SIMPLI method for spatially resolved tissue phenotyping at single cell resolution Preprint👇🏾biorxiv.org/content/10.110…

Dressler, Bortolomeazzi,Reda, Misetic, Sartini, Amelia Acha Sagredo, Montorsi, Francesca Ciccarelli & co present the 6th update of the Network of Cancer Genes database. It contains 3355 well-known or predicted cancer drivers, but shows there are still unknown drivers genomebiology.biomedcentral.com/articles/10.11…

This is a tour de force and transformative study led by Maxime Dhainaut and Brian Brown Lipschultz Precision Immunology Institute describing a spatial CRISPR genomics screen to identify regulators that drive cell composition and spatial organization in the tumor microenvironment cell.com/cell/fulltext/…

Can we break the glass ceiling of PD1/PDL1 inhibition? In the #COAST phase 2 trial, stage III NSCLC pts were randomized after CT/RT to durvalumab +/- oleclumab (anti-CD73) or monalizumab (anti-NKG2A). Both study arms showed doubled ORR & prolonged PFS. ascopubs.org/doi/abs/10.120…

Very proud to be inducted today along incredible scientists National Academy of Sciences and very grateful to many people and institutions that led me here. Starting with my Med school mentors in Algiers including my parents who taught me intellectual engagement , discipline & rigor (1/x)

Great paper showing the involvement of MHC II in shaping tumour visibility, anti-tumour immunity and ICB efficacy. Nicely complementing Marty R et al’s findings a few years ago in Cell nature.com/articles/s4158…

After a break from Twitter, I am happy to post Hrvoje Misetic and Reda tour the force to understand how cancer genes impact on and are impacted by nearby immune cells. Great clinical insights from Jean-Pierre Jeannon. 🙏 to Science and Innovation at Cancer Research UK and Guy’s & St Thomas’ Charity. 👇🏽 biorxiv.org/content/10.110…

Check out our deep dive into the systems-level and functional characteristics of cancer driver genes involved in the tumour-immune interplay! Was really fun working on this with my partner in crime Hrvoje Misetic and thankful to Francesca Ciccarelli and Jean-Pierre Jeannon

'Mechanisms driving the immunoregulatory function of cancer cells' nature.com/articles/s4156…

Adaptive priming but innate killing: how CD8 T cells can kill MHC I-null tumour cells biorxiv.org/content/10.110…

Thrilled to begin my tenure as the new president of International Union of Immunological Societies! We are working toward demystifying immunology research, fostering global collaborations & bringing new immunotherapies to patients everywhere 🤝 Read more here: iuis.org/about/who-we-a…

Nature research paper: Y chromosome loss in cancer drives growth by evasion of adaptive immunity go.nature.com/46iUGhu

Amazing and dogma-challenging work showing how primed CD8+ T cells can eliminate MHCI-null tumour cells via an innate-like mechanism. Congratulations!

Miriam Merad, MD, PhD, Elected to the National Academy of Medicine for Seminal Work in Immunology and Cell Biology | Mount Sinai - New York shar.es/agmF0C Icahn School of Medicine at Mount Sinai Lipschultz Precision Immunology Institute National Academy of Medicine

Only few places left! 🧐 Next Cam Comp Onco meeting ⏲️ March 15th, 3-6 pm 🛖 hosted by AZ at the DISC 📢 Oscar M Rueda Raquel Manzano 🧬🇪🇺🇪🇸 Reda ❗️❗️Register by march 10th❗️❗️ forms.office.com/e/iRW1Eak3t6

Join us for a great scientific get-together in our brand new DISCovery centre. Looking forward!